Virtual Poster Session in Hematology - prIME Oncology
Virtual Poster
Virtual Poster

Virtual Poster Session in Hematology

Key Data Presented During the 2018 Hematology Annual Meeting in San Diego

View Activities

Not a member of My prIME? Join now for instant access.

The information in this activity is intended for healthcare professionals based outside of the United States. This activity may contain information on products outside the approved indications where you practice.

Stay updated on recent hematology poster presentations from the 2018 Hematology Annual Meeting in San Diego. View experts presenting clinical trial data and download presentation slides. Don’t miss out!

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

IME

IME

Release Date

Release Date

Dec 14, 2018

Expiration Date

Dec 14, 2019

AML

Jorge Cortes, MD

Abstract #26: Maturing clinical profile of IMGN779, a next-generation CD33-targeting antibody-drug conjugate, in patients with relapsed or refractory acute myeloid leukemia

Featured Expert: Jorge Cortes, MD

Naval G. Daver, MD

Abstract #27: A phase I, first-in-human study evaluating the safety and preliminary antileukemia activity of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia and other

Featured Expert: Naval G. Daver, MD

Richard F. Schlenk, MD

Abstract #81: Gemtuzumab ozogamicin in NPM1-mutated acute myeloid leukemia (AML): Results from the prospective randomized AMLSG 09-09 phase III study

Featured Expert: Richard F. Schlenk, MD

Daniel A. Pollyea, MD

Abstract #285: Venetoclax in combination with hypomethylating agents induces rapid, deep, and durable responses in patients with AML ineligible for intensive therapy

Featured Expert: Daniel A. Pollyea, MD

Dennis Kim, MD, PhD

Abstract #662: Radius: A phase 2 randomized trial investigating standard of care ± midostaurin after allogeneic stem cell transplant in FLT3-ITD–mutated AML

Featured Expert: Dennis Kim, MD, PhD

Mark J. Levis, MD

Abstract #1458: Impact of minimal residual disease and achievement of complete remission/complete remission with partial hematologic recovery (CR/CRh) on overall survival following treatment with gilteritinib in patients with relapsed/refractory (r/r) acute myeloid leukemia (AML) with FLT3 mutations

Featured Expert: Mark J. Levis, MD

Maria Teresa Voso, MD

Abstract #2668: Ratify (Alliance 10603): Prognostic impact of FLT3 tyrosine kinase domain (TKD) and NPM1 mutation status in patients with newly diagnosed acute myeloid leukemia (AML) treated with midostaurin or placebo plus standard chemotherapy

Featured Expert: Maria Teresa Voso, MD

CML

Gabriele Gugliotta, MD, PhD

Abstract #458: Outcome of 472 chronic myeloid leukemia patients treated with frontline nilotinib: A Gimema CML WP analysis

Featured Expert: Gabriele Gugliotta, MD, PhD

Dennis Kim, MD, PhD

Abstract #787: Second attempt of TKI discontinuation with dasatinib for treatment-free remission after failing first attempt with imatinib: Treatment-free remission accomplished by dasatinib (TRAD) trial

Featured Expert: Dennis Kim, MD, PhD

Delphine Rea, MD, PhD

Abstract #792: Asciminib, a specific allosteric BCR-ABL1 inhibitor, in patients with chronic myeloid leukemia carrying the T315I mutation in a phase 1 trial

Featured Expert: Delphine Rea, MD, PhD

Fabrizio Pane, MD

Abstract #1750: International, prospective study comparing nilotinib versus imatinib with early switch to nilotinib to obtain sustained treatment-free remission in patients with chronic myeloid leukemia. A Gimema and HOVON study

Featured Expert: Fabrizio Pane, MD

Neil P. Shah, MD, PhD

Abstract #4253: Updated 18-month results from Dasfree: A study evaluating dasatinib discontinuation in patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP) and deep molecular response (DMR)

Featured Expert: Neil P. Shah, MD, PhD

MPN

Lucia Masarova, MD

Abstract #352: Updated results of phase 2 study of ruxolitinib in combination with 5-azacitidine in patients with myelofibrosis

Featured Expert: Lucia Masarova, MD

John Mascarenhas, MD

Abstract #577:   Results of the Myeloproliferative Neoplasms – Research Consortium (MPN-RC) 112 randomized trial of pegylated interferon alfa-2a (PEG) versus hydroxyurea (HU) therapy for the treatment of high risk polycythemia vera (PV) and high risk essential thrombocythemia (ET)

Featured Expert: John Mascarenhas, MD

John Mascarenhas, MD

Abstract #685: Imetelstat is effective treatment for patients with intermediate-2 or high-risk myelofibrosis who have relapsed on or are refractory to Janus kinase inhibitor therapy: Results of a phase 2 randomized study of two dose levels

Featured Expert: John Mascarenhas, MD

Srdan Verstovsek, MD, PhD

Abstract #1753: Long-term efficacy and safety (5 Years) in RESPONSE, a phase 3 study comparing ruxolitinib (rux) with best available therapy (BAT) in hydroxyurea (HU)-resistant/intolerant patients (pts) with polycythemia vera (PV)

Featured Expert: Srdan Verstovsek, MD, PhD

Lucia Masarova, MD

Abstract #1764: Efficacy and safety of pomalidomide in combination with prednisone in patients with myelofibrosis and anemia – Final results of a prospective phase 2 study

Featured Expert: Lucia Masarova, MD

CAR T

Jae H. Park, MD

Abstract #224: A phase I first-in-human clinical trial of CD19-targeted 19-28z/4-1BBL “armored” CAR T cells in patients with relapsed or refractory NHL and CLL including Richter’s transformation

Featured Expert: Jae H. Park, MD

Stephan A. Grupp, MD, PhD

Abstract #895: Updated analysis of the efficacy and safety of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory (r/r) acute lymphoblastic leukemia

Featured Expert: Stephan A. Grupp, MD, PhD

David A. Sallman, MD

Abstract #902: Remissions in relapse/refractory acute myeloid leukemia patients following treatment with NKG2D CAR-T therapy without a prior preconditioning chemotherapy

Featured Expert: David A. Sallman, MD

Gilles Salles, MD, PhD

Abstract #1684: Sustained disease control for adult patients with relapsed or refractory diffuse large B-cell lymphoma: An updated analysis of Juliet, a global pivotal phase 2 trial of tisagenlecleucel

Featured Expert: Gilles Salles, MD, PhD

Sattva Neelapu, MD

Abstract #2967: 2-year follow-up and high-risk subset analysis of Zuma-1, the pivotal study of axicabtagene ciloleucel (axi-cel) in patients with refractory large B cell lymphoma

Featured Expert: Sattva Neelapu, MD

Benign Hematology

Yi-Bin Chen, MD

Abstract #601: Results from REACH1, a single-arm phase 2 study of ruxolitinib in combination with corticosteroids for the treatment of steroid-refractory acute graft-vs-host disease

Featured Expert: Yi-Bin Chen, MD

Peter Bader, MD, PhD

Abstract #603: Children and adults with steroid-refractory acute graft-versus-host disease respond to treatment with the mesenchymal stroma cell preparation “MSC-Ffm”: Treatment results for 92 consecutive patients

Featured Expert: Peter Bader, MD, PhD

Darla K. Liles, MD

Abstract #1082: Established prevention of vaso-occlusive crises with crizanlizumab is further improved in patients who follow the standard treatment regimen: Post-hoc analysis of the phase II sustain study

Featured Expert: Darla K. Liles, MD

Titilola S. Akingbola, MBBS, FWACP

Abstract #3656: Maximum tolerated dose versus fixed low-dose hydroxyurea for treatment of adults with sickle cell anemia – Retrospective comparison of two studies

Featured Expert: Titilola S. Akingbola, MBBS, FWACP

  • Titilola S. Akingbola, MBBS, FWACPUniversity of Ibadan College of Medicine
    University College Hospital
    Ibadan, Nigeria
  • Peter Bader, MD, PhDUniversity Hospital Frankfurt
    Frankfurt, Germany
  • Yi-Bin Chen, MDMassachusetts General Hospital
    Boston, Massachusetts, United States
  • Jorge Cortes, MDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Naval G. Daver, MDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Stephan A. Grupp, MD, PhDChildren’s Hospital of Philadelphia
    Philadelphia, Pennsylvania, United States
  • Gabriele Gugliotta, MD, PhD University of Bologna
    Bologna, Italy
  • Dennis Kim, MD, PhDPrincess Margaret Cancer Centre
    University of Toronto
    Toronto, Ontario, Canada
  • Mark J. Levis, MD Sidney Kimmel Comprehensive Cancer Center
    Johns Hopkins University
    Baltimore, Maryland, United States
  • Darla K. Liles, MDEast Carolina University
    Greenville, North Carolina, United States
  • Lucia Masarova, MD The University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • John Mascarenhas, MDIcahn School of Medicine at Mount Sinai
    New York, New York, United States
  • Sattva Neelapu, MDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Fabrizio Pane, MD Federico II University of Naples
    Naples, Italy
  • Jae H. Park, MDMemorial Sloan Kettering Cancer Center
    New York, New York, United States
  • Daniel A. Pollyea, MDUniversity of Colorado
    Denver, Colorado, United States
  • Delphine Rea, MD, PhDHôpital Saint-Louis
    Paris, France
  • Gilles Salles, MD, PhDUniversity of Lyon
    Lyon, France
  • David A. Sallman, MDH. Lee Moffitt Cancer Center
    Tampa, Florida, United States
  • Richard F. Schlenk, MDNational Center of Tumor Diseases Heidelberg
    Heidelberg, Germany
  • Neil P. Shah, MD, PhDUniversity of California, San Francisco
    San Francisco, California, United States
  • Srdan Verstovsek, MD, PhDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Maria Teresa Voso, MDDepartment of Biomedicine and Prevention
    University of Rome Tor Vergata
    Rome, Italy

This educational activity is designed to meet the needs of practicing hematologists, oncologists, oncology nurses, researchers, and other health care professionals involved and/or interested in the management of patients with hematologic malignancies and their complications.

After successful completion of this educational activity, participants should be able to:

  • Evaluate clinical evidence supporting novel therapeutic strategies in hematologic malignancies and compare with established treatment options
  • Select appropriate biomarkers for predicting therapeutic response in hematologic malignancies
  • Identify appropriate clinical trials in which to enroll patients with hematologic malignancies

This educational activity is supported by ImmunoGen and Novartis Oncology.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

prIME Oncology requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to prIME Oncology policy. prIME Oncology is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Akingbola has no relevant financial relationships to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Bader has disclosed that he has received royalty fees from Medac. He is also a patent holder for Medac. He has received consulting fees from Celgene Corporation and Novartis Oncology. He also disclosed research grants from Medac, Neovii, and Riemser. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Chen has disclosed that he has received consulting fees from Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Cortes has disclosed that he has received consulting fees from Astellas, Daiichi-Sankyo, Novartis, and Pfizer. He has performed contracted research for Astellas, Daiichi-Sankyo, Immunogen, Novartis, and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Daver has disclosed that he has received consulting fees from Agios, Astellas, Bristol-Myers Squibb, Celgene Corporation, Daiichi-Sankyo, Incyte, Jazz Pharmaceuticals, Otsuka Pharmaceutical Co., Ltd., and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Gugliotta has disclosed that he has received consulting fees from Bristol-Myers Squibb, Incyte, Novartis Oncology, and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Grupp has disclosed that he has received consulting fees and performed contracted research for Novartis Oncology. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Kim has disclosed that he has received consulting fees and performed contracted research for BMS Canada. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Levis has disclosed that he has received consulting fees from Agios, Astellas, Daiichi-Sankyo, and Novartis. Has had performed contracted research for Astellas, Fuji Film, and Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Liles has disclosed that she has performed contracted research for Novartis Oncology. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Masarova has disclosed that she has no relevant financial relationships to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Mascarhenas has disclosed that he has received consulting fees from Celgene, CTI BioPharma, Incyte, and Roche. He has performed contracted research for CTI BioPharma, Janssen, Incyte, Merck, Novartis, Promedior, and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Neelapu has disclosed that he has received consulting fees from Celgene Corporation, Kite Pharma, Merck, Novartis Oncology, Pfizer, and Unum Therapeutics. He has also performed contracted research for Bristol-Myers Squibb, Cellectis, Karius, Kite Pharma, Merck, and Yoshida Pharmaceutical. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Pane has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Park has disclosed that he has received consulting fees from Amgen, GSK, Kite, and Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Pollyea has disclosed that he has received consulting fees from AbbVie, Agios, Astellas, Celgene Corporation, Celyad, DSI, Gilead, and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Rea has disclosed that she has received consulting fees from Bristol-Myers Squibb, Incyte, Novartis Oncology, and Pfizer. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Salles has disclosed that he has received consulting fees from June Pharma, Kite/Gilead, and Novartis Oncology. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Sallman has disclosed that he has received consulting fees from Celyad. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Schlenk has disclosed that he has received consulting fees and research funding from Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Shah has disclosed that he has performed contracted research for Bristol-Myers Squibb. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Verstovsek has disclosed that he has received consulting fees from Celgene, Constellation, Incyte, Novartis Oncology, Pragmatist, and Sierra. He has also performed research support for conducting clinical studies for Blueprint Medicines Corp, Celgene, CTI BioPharma Corp., Genentech, Gilead, Incyte Corporation, Novartis Oncology, NS Pharma, Promedior, and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Voso has disclosed that she has received consulting fees from Celgene and Novartis. She has also received fees for non-CME/CE services from, and performed contracted research for, Celgene. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

The employees of prIME Oncology have disclosed no relevant financial relationships.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.